Times Have Changed, But SOPHiA Hasn't

Bashar Issa profile picture
Bashar Issa


  • SOPH was one of the genome analysis pioneers, building an data analysis platform connecting the disparate silos of genomic information across the world.
  • However, it seems to have failed to adapt to the ever-changing landscape of the genetic testing industry.
  • The company's pitch to healthcare providers suffers a major flaw; its product is a Research Only Use device, limiting its use in patient care.
  • Since its foundation, more than a dozen gene diagnostic companies have entered the US market. Naturally, all these companies built their own biobank databases, limiting the advantage of SOPH.
UK Biobank Centre Begins Major Research Initative

Christopher Furlong/Getty Images News

Investment Thesis

When Swiss entrepreneur Dr. Jurgi Camblong established SOPHiA GENETICS (NASDAQ:SOPH) in the early years of the 2010s, his goal was to make the world's disparate genomic databases more accessible to healthcare providers, drug developers, and academic institutions. Many of these databases

This article was written by

Bashar Issa profile picture
Bashar is a contributing writer at Seeking Alpha, focusing on Long/Short investment ideas, with a geographic focus in North America. Before that, Bashar worked at an Investment Fund in the United Kingdom. He has a Master's degree in Finance from the Queen Mary University of London and a Bachelor's degree in Economics from Middlesex University.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.